ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company’s multiple sclerosis (MS) portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN) taking place April 10 to 17, in Toronto, Canada. The data presented will focus on Rebif® (interferon beta-1a), an established therapy for relapsing forms of MS, and Cladribine Tablets, a potential oral therapy for relapsing forms of MS currently under regulatory review in a number of countries.
“We have made a commitment as a leading company in this field to advance the treatment of multiple sclerosis and the underlying science,” said Bernhard Kirschbaum, PhD, Executive Vice President, Global Research and Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “The data presented at the upcoming AAN meeting will further contribute to the existing body of knowledge about Rebif® and Cladribine Tablets, as well as to a greater understanding of the disease.”
The following abstracts have been accepted for presentation at the 62nd AAN Annual Meeting:
>> CLICK to read these abstracts and more
0 comments:
Post a Comment